NICE recommends weekly injection for severe haemophilia B The National Institute for Health and Care Excellence said that marstacimab is a cost-effective treatment option for severe haemophilia B but not for severe haemophilia A.…
People with sickle cell disease face racism and ‘sub-standard care’, finds report A report commissioned by the NHS Race and Health Observatory recommends that more sickle cell training for healthcare professionals, including primary care, is needed.…
MHRA publishes ‘world first’ decentralised manufacturing guidance The guidance will inform the manufacture of medicines with a short shelf-life or highly personalised medicines at sites within or in close proximity to hospitals.…
Supporting pharmacists in improving the care delivered for people with cancer The Pharmaceutical Journal has launched a cancer ‘hub page’ and educational resources on blood cancer as part of continued partnership with BeiGene.… Supported content
Medicines derived from UK blood plasma distributed to NHS hospitals for ‘first time in a generation’ More than 250,000 litres of plasma from UK donors have been sent to human protein product manufacturer Octapharma to produce NHS medicines for the first time since a 1998 ban.…
Standard-dose DOACs not necessarily better than reduced dose, study results suggest Researchers found that “non-inferiority” of a reduced dose of direct oral anticoagulants could not be determined when compared with a standard dose, with “reliably low rates” of recurrent venous thromboembolism.…
NICE recommends once-weekly injection for severe blood clotting disorder Efanesoctocog alfa, a once-weekly treatment for patients with severe haemophilia A, removes the need for frequent dosing, owing to its effective bleeding control.…
NICE approves gene-editing sickle cell therapy for NHS in England Exagamglogene autotemcel, also known as exa-cel, is now recommended for NHS use, reversing previous draft guidance.…
New class of anticoagulant found to ‘overwhelmingly’ reduce bleeding events in patients with atrial fibrillation Experts say the results of this “exciting” two-year study of abelacimab “add to the growing evidence that inhibition of factor XI may preferentially impact thrombosis over haemostasis”.…
Nearly 92% of atrial fibrillation patients in England anticoagulated, says NHS adviser The UK Health Security Agency has achieved the figure five years ahead of its original 2029 target year by offering anticoagulation to nine in ten patients with atrial fibrillation.…
